Einloggen

Thematische Bibliographien / Bone resorption / Bücher

Bücher zum Thema „Bone resorption“

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Bone resorption.

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 10. März 2023

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Bücher für die Forschung zum Thema "Bone resorption" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Bücher für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Felix, Bronner, Farach-Carson Mary C. 1958- und Rubin Janet, Hrsg. Bone resorption. London: Springer, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Bronner, Felix, Mary C. Farach-Carson und Janet Rubin, Hrsg. Bone Resorption. London: Springer-Verlag, 2005. http://dx.doi.org/10.1007/b136184.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Harvey, Wilson. Prostaglandins in bone resorption. Boca Raton, Fla: CRC Press, 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Pierce, Angela Mary. Cellular mechanisms in bone and tooth resorption: Morphological studies in rats and monkeys. Stockholm: Kongl. Carolinska Medico Chirurgiska Institutet, 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Brown, R. James. Histological and compositional responses of bone to immobilization and other experimental conditions: Semi-annual report. San Francisco, Calif: Institute of Chemical Biology, University of San Francisco, 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Arun, Shanbhag, Rubash Harry E und Jacobs Joshua J. 1956-, Hrsg. Joint replacement and bone resorption: Pathology, biomaterials, and clinical practice. New York: Taylor & Francis, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Maria, Bijvoet Olav Leonardus, Hrsg. Bisphosphonate on bones. Amsterdam: Elsevier, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Åkesson, Louise. Panoramic radiography in the assessment of the marginal bone level. Malmö: Department of Oral Radiology, Faculty of Odontology, Lund University, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. Bern: H. Fleish, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Jonasson, Grethe. Mandibular alveolar bone mass, structure and thickness in relation to skeletal bone density in dentate women. Göteborg: Department of Orthodontics, Faculty of Odontology, The Sahlgrenska Academy at Göteborg University, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Loomer, Peter Michael. The direct effects of Porphyromonas Gingivalis 2561 on bone formation and mineral resorption in vitro. [Toronto: University of Toronto, Faculty of Dentistry], 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. 3. Aufl. New York: Parthenon Pub. Group, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. 2. Aufl. New York: Parthenon Pub. Group, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. 4. Aufl. San Diego: Academic Press, 2000.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

D, Rubens R., und European Conference on Clinical Oncology (5th : 1989 : London, England), Hrsg. The Management of bone metastases and hypercalcaemia by osteoclast inhibition: An international symposium held during the 5th European Conference on Clinical Oncology (ECCO 5), London, September 1989. Toronto: Hogrefe & Huber, 1990.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Congress, European Society for Medical Oncology. Disodium pamidronate (APD) in the treatment of malignancy-related disorders: An international symposium held during the 13th Congress of the European Society for Medical Oncology (ESMO), Lugano, Switzerland, October 1988. Toronto: Hogrefe & Huber, 1990.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Peter, Burckhardt, Hrsg. Disodium pamidronate (APD) in the treatment of malignancy-related disorders. Toronto: Huber, 1989.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Meyer, James L. I loved a boy: Confessions of a Roman Catholic priest. Royal Oak, Mich: Van Antwerp and Beale Publishers, 2007.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Meyer, James L. I loved a boy: Confessions of a Roman Catholic priest. Royal Oak, Mich: Van Antwerp and Beale Publishers, 2007.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Shorey, Seema. Differences in the degree to which osteoclasts from different parts of the skeleton employ cathepsin K and matrix metalloproteinases for bone resorption. Ottawa: National Library of Canada, 2002.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Tai, Victoria. The effects of leukotriene Bb4s on osteoclast formation and osteoclastic bone resorption and the role of osteoblastic cells in these processes. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Mundy, Gregory R. Bone remodeling and its disorders. London: Martin Dunitz, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Mundy, Gregory R. Bone remodeling and its disorders. London: Martin Dunitz, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Bronner, Felix, Janet Rubin und Mary C. Farach-Carson. Bone Resorption. Springer London, Limited, 2010.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Bronner, Felix, Janet Rubin und Mary C. Farach-Carson. Bone Resorption. Springer London, Limited, 2006.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Harvey, Wilson, und Alan Bennett. Prostaglandins in Bone Resorption. CRC Press, 2020. http://dx.doi.org/10.1201/9780429279195.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Harvey, Wilson, und Alan Bennett. Prostaglandins in Bone Resorption. Taylor & Francis Group, 2020.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Harvey, Wilson, und Alan Bennett. Prostaglandins in Bone Resorption. Taylor & Francis Group, 2020.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Harvey, Wilson, und Alan Bennett. Prostaglandins in Bone Resorption. Taylor & Francis Group, 2020.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Harvey, Wilson, und Alan Bennett. Prostaglandins in Bone Resorption. Taylor & Francis Group, 2019.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Harvey, Wilson, und Alan Bennett. Prostaglandins in Bone Resorption. Taylor & Francis Group, 2020.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Bone resorption, metastasis, and diphosphonates. New York: Raven Press, 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Shanbhag, Arun, Harry E. Rubash und Joshua J. Jacobs, Hrsg. Joint Replacement and Bone Resorption. CRC Press, 2005. http://dx.doi.org/10.1201/b14138.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Rubash, Harry E., Arun Shanbhag und Joshua J. Jacobs. Joint Replacement and Bone Resorption. Taylor & Francis Group, 2019.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

OGURA, HIDEAKI. Pharmacological Approach to the Study of the Formation and the Resorption Mechanism of Hard Tissues. MEDICO DENTAL MEDIA INTERNATIONAL, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Osteoblasts: Morphology, Functions and Clinical Implications. Nova Science Pub Inc, 2013.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Anderson, Paul, Borje Edgar Christopher Nordin und Howard Arthur Morris. Physiological Basis of Metabolic Bone Disease. Taylor & Francis Group, 2014.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Anderson, Paul, Borje Edgar Christopher Nordin und Howard Arthur Morris. Physiological Basis of Metabolic Bone Disease. Taylor & Francis Group, 2014.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Anderson, Paul, Howard A. Morris und B. E. Christopher Nordin. Physiological Basis of Metabolic Bone Disease. Taylor & Francis Group, 2017.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Anderson, Paul, Borje Edgar Christopher Nordin und Howard Arthur Morris. Physiological Basis of Metabolic Bone Disease. Taylor & Francis Group, 2014.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Rubash, Harry E., Arun Shanbhag und Joshua J. Jacobs. Joint Replacement and Bone Resorption: Pathology, Biomaterials and Clinical Practice. Taylor & Francis Group, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

(Editor), Arun Shanbhag, Harry E. Rubash (Editor) und Joshua J. Jacobs (Editor), Hrsg. Joint Replacement and Bone Resorption: Pathology, Biomaterials and Clinical Practice. Informa Healthcare, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Rubash, Harry E., Arun Shanbhag und Joshua J. Jacobs. Joint Replacement and Bone Resorption: Pathology, Biomaterials and Clinical Practice. Taylor & Francis Group, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Mansfield, Ian David. The synthesis of novel agents which inhibit tumour-stimulated bone resorption. 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

The relationship between bone mineral density and selected variables: An epidemiological perspective. 1990.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Javaid, Kassim. Paget’s disease of bone. Herausgegeben von Patrick Davey und David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0274.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Paget’s disease of bone is an uncommon bone disorder with increased bone resorption and disorganized bone formation of woven bone. Its cause is unclear; there is a clear genetic component but additional environmental factors are important, given the reduction in severity and prevalence in the UK. Paget’s disease is usually asymptomatic and detected by an unexplained raised alkaline phosphatase on routine biochemistry. Symptoms include focal bone pain, including headache. Other symptoms include bone deformity and complications such as fracture and nerve conduction. Paget’s disease can sometimes present with immobilization-associated hypercalcaemia or high-output cardiac failure, and rarely can transform to an osteosarcoma. This chapter addresses the clinical features, diagnosis, and management of Paget’s disease of bone.

47

Effects of prostaglandin Eb2s on chick bone rudiments in vitro: Studies on bone resorption and formation. Ottawa: National Library of Canada, 1990.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Wordsworth, B. P. Skeletal dysplasias. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0150.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Bone is metabolically active throughout life and metabolic disturbances may have wide-ranging consequences that are not restricted to altering its mechanics. The study of some genetic bone diseases has already provided remarkable insights into the normal regulation of bone metabolism. Skeletal dysplasias are developmental disorders of the chondro-osseous tissues commonly resulting in short stature, which is often disproportionate. The underlying mutations are often in the structural genes encoding components of the matrix but may also involve growth factors or cell signalling. In contrast, the dysostoses tend to affect single bones or groups of bones, reflecting the transient nature of the many different signalling factors to which they are responsive during development. Abnormalities of bone density (high or low) may be due to primary deficiency of bone matrix synthesis (e.g. osteogenesis imperfecta and hypophosphatasia) but may also reflect an imbalance between bone formation and resorption. This may be caused by abnormalities of bone formation (e.g. hyperostosis/sclerosteosis and osteoporosis pseudoglioma syndrome) or bone resorption (e.g. classic osteopetrosis and fibrous dysplasia).

49

Ralston, Stuart H. Paget’s disease of bone. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0144.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Paget's disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.

50

Ralston, Stuart H. Paget’s disease of bone. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0144_update_001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Paget’s disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.